ZEISS achieves another milestone on regulatory pathway
Filed with ASX ·
6ix hasn’t read this filing yet.
Optiscan Imaging Limited on 6ix
Earlier from Optiscan Imaging
- Suspension from Official Quotation
- Clinical Trial - Assessment of Breast Cancer Margin
- Appendix 4E and 2018 Annual Report
- Market Update
- ZEISS CONVIVO and Appointment of Interim Executive Chairman
Later from Optiscan Imaging
- Reinstatement to Official Quotation
- OptiScan technology used in research at major cancer centre
- Collaboration Agreement with Summit Biomedical Imaging LLC
- Appendix 4D and Financial Statements - 31 Dec 2018
- OptiScan March 2019 Presentation
Follow Optiscan Imaging into a list and get an email when it puts out news.
Follow Optiscan Imaging